Goldberg–Maxwell Syndrome

Goldberg–Maxwell syndrome is an old name from a 1958 BMJ report describing three siblings with a disorder of sex development. Today, this same entity is understood as androgen insensitivity syndrome (AIS)—a genetic condition where a person with one X and one Y chromosome (46,XY) makes typical amounts of androgens (like testosterone) but the body’s cells can’t respond to them because the androgen receptor doesn’t work properly. As a result, genital development before birth and puberty does not follow the typical “male” pathway; in the complete form, the external anatomy looks typically female, puberty occurs via aromatization of testosterone to estrogen (so breasts develop), but there is no uterus or cervix, the vagina may be shorter, the gonads are testes (often undescended), and fertility is affected. AIS spans a spectrum: complete (CAIS), partial (PAIS), and mild (MAIS). The condition is usually due to pathogenic variants in the androgen receptor (AR) gene on Xq11-12 and is managed with individualized, multidisciplinary care that addresses health, development, sexuality, identity, and long-term tumor risk of retained gonads. MedlinePlus+3PubMed+3NCBI+3

Goldberg–Maxwell syndrome is an old name for what doctors now call androgen insensitivity syndrome (AIS). In AIS, a person has one X and one Y chromosome (genetic pattern 46,XY) and makes typical male hormones (androgens), but the body’s cells cannot respond to those hormones normally because the androgen receptor is not working properly. As a result, body development before birth and at puberty may follow a more female pattern, leading to findings such as typical female external genitalia (in complete AIS), primary amenorrhea, sparse or absent pubic/axillary hair, and undescended testes. The eponym “Goldberg–Maxwell” appears in older medical literature describing this same condition. PubMed+3NCBI+3NCBI+3

AIS forms a spectrum. In complete AIS (CAIS), tissues are fully insensitive to androgens, so the external genitalia appear typically female. In partial AIS (PAIS), androgen response is reduced, so genital appearance can be in-between (for example, hypospadias, micropenis, or ambiguous genitalia). In mild AIS (MAIS), external genitalia are typically male, but problems such as male-pattern infertility or pubertal gynecomastia can occur. NCBI+1

Another names

Doctors and databases list several older or alternate names for this same condition, including Goldberg–Maxwell syndrome, testicular feminization syndrome, and Morris syndrome. Modern usage prefers androgen insensitivity syndrome (AIS). Reputable catalogs (Orphanet, NORD/MONDO) and reviews confirm these synonyms. Orpha+2National Organization for Rare Disorders+2

Types

Complete AIS (CAIS). External anatomy looks typically female; puberty brings breast development without menses (primary amenorrhea). No uterus or cervix; testes are present (often intra-abdominal or in the inguinal canal). Gender identity is usually female; care focuses on timing of gonadectomy, hormone replacement after gonadectomy, bone health, and sexual health. NCBI+1

Partial AIS (PAIS). Varying degrees of undervirilization at birth; genital appearance ranges from mostly female to ambiguous to mostly male with hypospadias/undescended testes. Puberty can include gynecomastia. Management may include masculinizing surgery or orchiopexy if raised male, consideration of gonadectomy if raised female, and tailored hormone therapy. NCBI

Mild AIS (MAIS). External genitalia are typically male; presentations include infertility, gynecomastia, or reduced body hair. Treatment may involve fertility counseling, targeted hormone therapy, and, if desired, gynecomastia management. NCBI

Causes

AIS is caused by problems that disable or reduce the function of the androgen receptor (AR), a protein inside cells that “reads” androgen signals and turns on specific genes. Below are common, well-described ways this can happen. (Items 1–13 are specific mutation types/locations; 14–20 are additional biologic mechanisms recognized in the literature.)

1. Missense mutations in the AR gene that change one amino acid and weaken hormone binding or gene activation. NCBI+1

2. Nonsense mutations that create a premature stop signal and truncate the receptor. NCBI

3. Frameshift mutations (small insertions/deletions) that disrupt the AR protein. NCBI

4. Splice-site mutations that cause exon skipping or intron retention, producing a faulty receptor. NCBI

5. Large deletions in the AR gene removing essential domains. NCBI

6. Duplications or complex rearrangements that disturb AR structure/regulation. NCBI

7. Mutations in the N-terminal transactivation domain (impairing co-activator recruitment). ScienceDirect

8. Mutations in the DNA-binding domain (zinc finger region) that reduce DNA targeting. NCBI

9. Mutations in the hinge/nuclear localization region that block AR movement into the cell nucleus. ScienceDirect

10. Mutations in the ligand-binding domain (LBD)—especially the helix-12 region—weakening androgen binding. ScienceDirect

11. Promoter or regulatory mutations that reduce AR gene expression. ScienceDirect

12. De novo AR mutations that arise for the first time in the family (not inherited). Wikipedia

13. Somatic or germline mosaicism in a parent or the proband, causing patchy AR dysfunction. Wikipedia

14. Pathogenic variation affecting AR co-regulator interaction surfaces, limiting gene activation even when hormone binds. ScienceDirect

15. Post-translational modification defects (e.g., abnormal AR phosphorylation/ubiquitination described in reviews) that destabilize AR function. ScienceDirect

16. Skewed X-inactivation in 46,XX carriers can modify expression patterns (helps explain variable lab findings in carriers; the proband with 46,XY is affected because there is only one X). NCBI

17. Pathogenic variants altering AR interaction with heat-shock proteins required for proper folding. ScienceDirect

18. Polyglutamine tract length variants at extremes may modulate AR transactivation capacity (context from AR biology literature). ScienceDirect

19. Epigenetic down-regulation (e.g., promoter methylation described in AR research) that reduces available receptor. ScienceDirect

20. X-linked inheritance with a pathogenic AR variant transmitted by a carrier mother (the mechanism that explains most familial AIS). NCBI

Note: Disorders of androgen production (e.g., 5-alpha-reductase deficiency) can look similar but are not Goldberg–Maxwell/AIS; in AIS, androgens are present but the receptor cannot act on them. NCBI

Symptoms and signs

1. Primary amenorrhea (no first period) in a teen with otherwise typical breast development. NCBI

2. Typical female external genitalia at birth in CAIS, often with short/blind-ending vagina. NCBI

3. No uterus or cervix on imaging; internal testes present (often undescended). NCBI

4. Inguinal or labial lumps in infants or children (undescended testes found during hernia repair). NCBI

5. Sparse or absent pubic and underarm hair at puberty (because hair follicles need androgen action). NCBI

6. Normal breast development at puberty due to conversion of androgens to estrogens. NCBI

7. Tall stature or taller-than-family trend is common but variable. NCBI

8. Gynecomastia in boys/men with PAIS or MAIS. NCBI

9. Hypospadias, micropenis, or ambiguous genitalia in PAIS at birth. Orpha

10. Infertility in MAIS or PAIS; gonadal function is usually inadequate for fertility. NCBI

11. Limited facial/body hair in adolescence for PAIS/MAIS. NCBI

12. Psychosocial stress around identity, puberty, disclosure, and medical decisions (important for care planning). NCBI

13. Hernias in infancy (a clue to undescended testes in CAIS). NCBI

14. Reduced bone density risk over time if sex-steroid replacement is not optimized after gonadectomy. ScienceDirect

15. Possible increased risk of gonadal tumors in undescended testes, with risk influenced by age and location; timing of surgery is individualized. ScienceDirect

Diagnostic tests

(Grouped exactly as requested; each item explained in one simple paragraph.)

Physical examination

1. General growth and body habitus. Height, arm-span, and proportions are checked because reduced androgen action can affect growth patterns. Clinicians also review past surgery (e.g., hernia repair) that may have revealed gonadal tissue. NCBI

2. Breast and hair Tanner staging. Typical breast development with sparse pubic/axillary hair suggests AIS at puberty. NCBI

3. External genital inspection. In CAIS, genitalia are typically female; in PAIS, findings range from hypospadias to ambiguous genitalia. A careful, respectful exam documents details to guide testing. NCBI+1

4. Palpation of the groin/labia. Doctors feel for inguinal or labial masses that may be undescended testes—often first noticed during a “hernia” evaluation. NCBI

Manual tests

5. Stretched penile length measurement (in infants with undervirilization). This standardized measurement helps distinguish PAIS from other causes of micropenis. NCBI

6. Prader staging (virilization scale). Clinicians grade external virilization to communicate severity and track outcomes. NCBI

7. Quigley scale for AIS phenotype. This widely used AIS-specific scale ranks external appearance from typical female (CAIS) to typical male (MAIS). NCBI

8. Gentle vaginal length/introital assessment in CAIS. A short/blind-ending vagina supports the diagnosis and informs counseling and options for dilation or surgical creation if desired later. ScienceDirect

Laboratory and pathological tests

9. Karyotype (chromosomes). AIS typically shows 46,XY. This is a key first step when primary amenorrhea or ambiguous genitalia is present. NCBI

10. Serum testosterone. In AIS, testosterone is normal to high for male range (age-appropriate), because the testes make it but tissues cannot use it effectively. NCBI

11. LH and FSH. LH is often elevated (feedback loop), and FSH is normal to mildly high. This hormone pattern supports androgen resistance. NCBI

12. Estradiol and SHBG. Estradiol may be in the female range due to aromatization; SHBG may be higher and modifies free hormone levels. These help complete the endocrine picture. NCBI

13. AMH (anti-Müllerian hormone) and inhibin-B. Produced by Sertoli cells; results help confirm functioning testicular tissue even when the uterus is absent. NCBI

14. hCG stimulation test (when needed). Demonstrates that testes can produce testosterone (ruling in receptor-level resistance rather than production defects). NCBI

15. AR gene testing (sequencing ± MLPA). Identifies pathogenic variants in the androgen receptor gene and can confirm AIS and inform family counseling. NCBI

16. Gonadal pathology or tumor markers when tumors are suspected. Pathology may show hyalinized seminiferous tubules; AFP/β-hCG/LDH help screen for germ-cell tumors in clinical contexts. ScienceDirect

Electrodiagnostic tests

17. No disease-specific electrodiagnostic test is required. AIS is diagnosed by exam, hormones, genetics, and imaging. If a patient is having anesthesia or surgery, an ECG may be done for routine safety, but it does not diagnose AIS. NCBI

Imaging tests

18. Pelvic and inguinal ultrasound. Looks for undescended testes and confirms the absence of a uterus; it is non-invasive and commonly used. NCBI

19. Pelvic MRI. Gives a clearer map of gonad location (groin/abdomen) and nearby structures to plan surgery, when needed. ScienceDirect

20. Bone density scan (DXA). Used for long-term care because estrogen/testosterone balance and timing of gonad removal influence bone health. ScienceDirect

Non-pharmacological treatments (therapies & others)

1. Shared decision-making & staged disclosure. Provide age-appropriate, compassionate disclosure about diagnosis and options, involve the person (and parents if a minor), and respect autonomy. This reduces shame, anxiety, and improves satisfaction with care. Many societies (e.g., ESPE) emphasize informed consent and self-determination. eurospe.org

2. Dedicated psychosocial care. Early and ongoing counseling for individuals and families helps with identity questions, relationships, and coping. Preventive long-term counseling is recommended in DSD conditions. ScienceDirect

3. Peer-support networks. Connecting with others living with AIS/DSD reduces isolation and improves mental health and sexual well-being. Clinics often partner with patient groups. (General DSD care guidance supports this model.) eurospe.org

4. Sexual health education. Gentle, honest education about anatomy, arousal, lubrication, pain prevention, and consent empowers people and can improve sexual function and satisfaction. NCBI

5. Pelvic floor physical therapy. Therapist-guided relaxation, breathing, and dilator coaching can ease penetration difficulties and dyspareunia associated with a short or tight vagina in CAIS/PAIS. nhs.uk

6. Vaginal dilation (first-line when lengthening is desired). Graduated dilators, used consistently with guidance, often achieve lengthening without surgery; many services delay any intervention until after puberty to support autonomy and spontaneous changes. nhs.uk

7. Bone-health program. Weight-bearing/resistance exercise, calcium-rich diet, vitamin D sufficiency, and smoking avoidance protect bone—especially important after gonadectomy or when estrogen is suboptimal. NCBI

8. Cancer surveillance when gonads are retained. If a person chooses to keep gonads, structured surveillance (exam, ultrasound, and shared plan for investigating pain/masses) can detect changes early; tumor risk remains low before adulthood but rises with age. PMC+1

9. Fertility counseling. Discuss present limits (CAIS infertility; limited fertility in some MAIS) and evolving reproductive options (e.g., adoption, partner reproduction, experimental avenues). NCBI

10. School/work coaching. Practical plans for privacy, bathroom/locker challenges, and medical leave for procedures support quality of life. NCBI

11. Body image and gender-expression support. Affirming clothing, voice, and styling coaching can improve confidence; these are non-medical but impactful. NCBI

12. Relationship/partner counseling. Couple-focused sessions help with communication, intimacy planning, and expectations around penetrative sex. NCBI

13. Nutrition coaching. Adequate protein, calcium, vitamin D, and overall balanced nutrition support bone and general health, especially around surgeries or HRT adjustments. NCBI

14. Post-operative rehab plans. When surgery is chosen (e.g., gonadectomy or vaginoplasty), structured aftercare (wound care, graded activity, pain strategies) speeds recovery and outcomes. NCBI

15. Gynecomastia non-surgical measures (for PAIS/MAIS choosing male pathway). Weight management, resistance training for chest contour, and realistic expectations may reduce the desire for surgery. NCBI

16. Puberty-timing counseling. Families often choose to defer irreversible procedures until the young person can participate in decisions after puberty. This is supported by modern DSD ethics guidance. eurospe.org

17. Transition to adult care program. A formal handover from pediatric to adult endocrinology/gynecology/urology improves adherence to surveillance, HRT, and bone health plans. Oxford Academic

18. Pain and pelvic comfort strategies. Mindful breathing, lubricants, and gradual exposure approaches help those experiencing introital pain. nhs.uk

19. Genetic counseling for the family. Explain X-linked inheritance, carrier testing, recurrence risk, and options in future pregnancies. NCBI

20. Care navigation (“single-door” clinics). Multidisciplinary teams (endocrinology, gynecology/urology, psychology, genetics, pelvic PT) reduce fragmented care and improve satisfaction. NCBI

Drug treatments

Note: Drug choices depend on the person’s anatomy, goals, and whether gonads are present. AIS cells don’t respond well to androgens; so “antiandrogens” or “more testosterone” are not universally useful—plans are individualized. Evidence focuses on symptom control, puberty, bone health, and post-gonadectomy replacement. NCBI

1. 17β-Estradiol (oral). For individuals with CAIS after gonadectomy, oral estradiol (e.g., 1–2 mg/day, then titrate) supports breast contour, bone health, and vasomotor symptom control. Start after surgery or if endogenous estrogen is inadequate. Side effects: nausea, headache, VTE risk (dose-related). NCBI

2. Transdermal estradiol patch/gel. Patches (e.g., 50–100 µg/day) or gels provide physiologic estrogen without first-pass hepatic effects; often preferred for lower thrombotic risk and better bone outcomes. Monitor symptoms and serum estradiol/LH. Oxford Academic

3. Micronized progesterone (select situations). Generally not required in CAIS because there is no uterus; may be used short-term for sleep/anxiety benefits but is not routine. NCBI

4. Topical vaginal estrogen. Low-dose estradiol cream can aid comfort with dilation/sexual activity by improving vaginal epithelium—used intermittently under guidance. nhs.uk

5. Testosterone (systemic; PAIS or MAIS choosing male pathway). High-dose testosterone cypionate or gels may improve virilization, energy, and bone/muscle in those with partial receptor function; doses are individualized and effects vary. Monitor hematocrit, lipids, mood. NCBI

6. Dihydrotestosterone (DHT) gel (specialist use). Occasionally tried in PAIS to target AR with a non-aromatizable androgen; responses are variable and evidence limited. The Lancet

7. Tamoxifen (SERM) for gynecomastia (PAIS/MAIS raised male). Short courses may reduce breast tenderness/size in puberty; watch for thrombotic risk and mood changes. MDPI

8. Bisphosphonates (e.g., alendronate). Consider in adults with osteoporosis or fragility fractures after optimizing estrogen/vitamin D/calcium. Monitor BMD; watch for GI irritation, rare ONJ/atypical fractures with long-term use. NCBI

9. Calcium (as a medication-grade supplement). 1000–1200 mg elemental/day (diet+supplements) supports bone health alongside estrogen. Avoid excess; divide doses for absorption. NCBI

10. Vitamin D3 (cholecalciferol). Dose to maintain 25-OH vitamin D in target range (commonly 800–2000 IU/day; individualized). Supports calcium absorption and bone. NCBI

11. Analgesics (peri-operative). Short courses of acetaminophen/NSAIDs after gonadectomy, hernia repair, or vaginoplasty; avoid prolonged opioid use. NCBI

12. Topical lidocaine gel. For localized introital discomfort during early dilation or sexual activity; use sparingly with counseling. nhs.uk

13. Antibiotic prophylaxis (procedure-specific). As per surgical protocols for urologic/gynecologic procedures when indicated. NCBI

14. Antiemetics (peri-anesthesia). To reduce nausea/vomiting during surgical care, tailored to risk. NCBI

15. Estrogen after early gonadectomy (adolescents). If gonads are removed before spontaneous puberty, carefully titrated estradiol is used to induce puberty (breast development, growth-plate maturation), following pediatric endocrine guidelines. Oxford Academic

16. Transdermal estradiol long-term (adults). Often preferred maintenance for bone and cardiovascular risk profile; adjust to symptoms and labs. Oxford Academic

17. Topical lubricants (medical-grade). Silicone or water-based lubricants reduce friction-related pain during dilation/sex (adjunct, not “drug therapy” per se but often dispensed as a medical product). nhs.uk

18. Testosterone gel “trial” (selected MAIS). Under specialist supervision, a time-limited trial can clarify symptom benefit (energy/libido) vs. side effects; discontinue if no response. NCBI

19. Selective use of GnRH analogs (rare). In complex pubertal scenarios to pause development while decisions are made; this is uncommon and requires expert teams. NCBI

20. Post-gonadectomy symptom rescue (short-term). Temporary dose adjustments or add-back strategies during hot flashes, night sweats, or mood symptoms while titrating estradiol. NCBI

Why no “antiandrogens”? In AIS the receptor is insensitive, so blocking androgens adds no benefit; therapy targets estrogen replacement after gonadectomy (if done), bone/sexual health, and individualized goals. NCBI

Dietary molecular supplements

1. Vitamin D3 (see above): dose to keep 25-OH D in range; aids bone. NCBI

2. Calcium: reach 1000–1200 mg/day total intake. NCBI

3. Protein-adequate diet or whey (if intake is low): supports lean mass with or without testosterone exposure. NCBI

4. Omega-3 fatty acids: general anti-inflammatory and cardiometabolic support during long-term HRT; adjunct only. NCBI

5. Iron (when deficient): menstruation is absent in CAIS, but peri-operative or dietary shortfalls can occur; supplement only if labs confirm deficiency. NCBI

6. B12/folate (if low): correct documented deficiencies to support energy and hematologic health. NCBI

7. Magnesium (if low): supports muscle function/sleep; supplement based on labs/tolerance. NCBI

8. Fiber supplement: assists bowel regularity during peri-operative periods and with reduced activity. NCBI

9. Probiotics (optional): may help post-antibiotic gut comfort; not disease-specific. NCBI

10. Multivitamin (baseline gaps): safety-first, low-dose formulation when diets are inconsistent; avoid megadoses. NCBI

No supplement corrects AR gene function; use supplements to support bone, recovery, and general health—not as “treatments” for AIS itself. NCBI

Immunity-booster / regenerative / stem-cell drugs

There are no validated immune-booster or stem-cell drugs that treat AIS or restore androgen receptor function. Any such claims should be avoided outside approved research. Focus on evidence-based HRT, bone health, and surgery when indicated. (Below are safe, practical “system-support” measures sometimes called “immune support,” but they are not disease-modifying.)

1. Seasonal vaccinations (e.g., influenza, COVID-19) according to national schedules keep people healthy through surgeries and clinic visits. NCBI

2. Vitamin D sufficiency supports immune function and bone; dose to targets. NCBI

3. Sleep optimization programs (behavioral): improves immune resilience, pain tolerance, and mood post-operatively. NCBI

4. Protein-adequate nutrition maintains lean mass and wound healing after procedures. NCBI

5. Aerobic + resistance exercise enhances cardiometabolic and bone health. NCBI

6. Smoking cessation reduces surgical and thrombotic risks on estrogen therapy. NCBI

Surgeries

1. Gonadectomy (removal of intra-abdominal/inguinal testes). Reason: reduce age-related tumor risk and allow stable HRT. Modern practice often defers until after puberty (late adolescence/adulthood) because pre-pubertal risk is low and endogenous puberty has benefits; many adults also choose surveillance instead. PubMed+1

2. Hernia repair (inguinal). Reason: CAIS may present as a “girl with hernia” due to a testis in the canal; repair prevents recurrence/complications. NCBI

3. Vaginoplasty (only if desired and dilation is insufficient). Reason: create/lengthen a vagina to improve comfort with penetrative sex; reserved for those who want it after counseling. nhs.uk

4. Orchiopexy (PAIS choosing male pathway). Reason: move testis into scrotum to aid surveillance, possibly reduce tumor risk, and support hormonal function. NCBI

5. Gynecomastia reduction (PAIS/MAIS raised male). Reason: persistent, painful, or distressing breast tissue despite medical measures. Cleveland Clinic

Prevention

1. Avoid smoking (thrombosis risk on estrogen; wound healing). Oxford Academic

2. Stay active (bone and heart). NCBI

3. Adhere to HRT after gonadectomy to protect bone and well-being. NCBI

4. Don’t rush irreversible surgery in children; revisit choices when the person can participate. eurospe.org

5. Keep surveillance appointments if retaining gonads. PMC

6. Ensure vitamin D/calcium sufficiency year-round. NCBI

7. Use lubrication for comfort with dilation/sex to prevent pain and trauma. nhs.uk

8. Plan transitions from pediatric to adult care. Oxford Academic

9. Seek peer/community support to reduce isolation. eurospe.org

10. Maintain honest, supportive communication in families/relationships. NCBI

When to see doctors (red flags and routine care)

• Primary amenorrhea (no periods by ~15–16 years), especially with otherwise typical breast development. MedlinePlus

• Inguinal/labial mass in a child who appears female (possible testis/hernia). UpToDate

• Pelvic/inguinal pain, swelling, or a new lump if gonads are retained. PubMed

• Hot flashes, night sweats, mood changes, low libido, or bone pain after gonadectomy (may signal under-replacement). NCBI

• Planning pregnancy or fertility questions (for partners/family planning). NCBI

• Any decision about surgery or hormone therapy—seek an experienced DSD team. eurospe.org

What to eat and what to avoid

Eat more of:

1. Dairy/fortified alternatives (calcium).

2. Oily fish/fortified foods (vitamin D).

3. Lean proteins (muscle/bone).

4. Whole grains/legumes (energy, fiber).

5. Fruits/vegetables (micronutrients). NCBI

Limit/avoid:

1. Excess salt (bone/calcium loss).
2. Ultra-processed foods (metabolic risk).
3. Sugary drinks (weight, bone).
4. Heavy alcohol (bone, HRT interactions).
5. Smoking/vaping (bone/thrombosis). NCBI

FAQs

1. Is “Goldberg–Maxwell syndrome” the same as AIS?
   Yes. It’s a historical label for cases now recognized as androgen insensitivity syndrome. PubMed

2. What causes AIS?
   Mostly AR gene variants that limit the body’s response to androgens. NCBI

3. How is AIS diagnosed?
   By combining exam, karyotype (46,XY), hormone tests, imaging, and AR sequencing. MedlinePlus

4. Will someone with CAIS have periods?
   No. There’s no uterus/cervix, so no menstruation. MedlinePlus

5. Is tumor risk high?
   Before adulthood the risk is low; it rises with age. Timing of gonadectomy is individualized; many defer until after puberty. PubMed+1

6. Do people with CAIS need progesterone?
   Usually no, because there’s no uterus. Estrogen is the key replacement after gonadectomy. NCBI

7. Can AIS be “cured” or reversed?
   No. Care focuses on health, function, comfort, and life goals. NCBI

8. Can someone with PAIS be raised male?
   Yes—plans are individualized; may include surgery (orchiopexy/hypospadias repair) and tailored hormone therapy. Cleveland Clinic

9. What about fertility?
   CAIS: infertility. MAIS: infertility or subfertility possible; counseling advised. NCBI

10. Is dilation or surgery better for short vagina?
    Dilation is first-line and often sufficient; surgery is for selected cases after counseling. nhs.uk

11. What HRT is best after gonadectomy?
    Transdermal or oral estradiol—dose and route tailored to symptoms, labs, and risk profile. Oxford Academic

12. What about bone health?
    Ensure adequate estrogen, vitamin D/calcium, and weight-bearing exercise; treat osteoporosis if present. NCBI

13. Are antiandrogens useful?
    Not typically in AIS because receptors are insensitive. Management focuses on estrogen (post-gonadectomy) or individualized androgen use in PAIS/MAIS. NCBI

14. Who should be on the care team?
    Endocrinology, gynecology/urology, psychology, genetics, pelvic PT, primary care. NCBI

15. Where did the term come from?
    A 1958 BMJ paper reporting three siblings; modern nomenclature uses AIS. PubMed

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 17, 2025.